Table 3.
Univariate analysis of parent proxy-reported HRQoL
| Parameter (numbers) | Parent-Proxy Reported PedsQL | |||||
|---|---|---|---|---|---|---|
| Total Core Score | Physical Score | Psychosocial Score | Emotional Score | Social Score | School Score | |
| Distinction* or Correlation** Coefficient (P Value) | ||||||
| Age** | 0.003 (0.99) | 0.06 (0.73) | -0.03 (0.84) | -0.07 (0.67) | 0.07 (0.66) | -0.10 (0.55) |
| Sex: F vs M* 25/15 | 3.0 (0.64) | 7.5 (0.33) | 0.8 (0.89) | 1.4 (0.83) | -0.4 (0.96) | -1.2 (0.87) |
| Race: Other vs Wh.* (3/37) | 13.1 (0.26) | 15.3 (0.28) | 12.1 (0.29) | 10.1 (0.40) | 12.5 (0.37) | 12.7 (0.31) |
| Income** | 0.06 (0.72) | 0.01 (0.93) | 0.08 (0.63) | -0.07 (0.69) | 0.07 (0.68) | 0.19 (0.25) |
| Ependymoma vs Other* (22/18) | 1.5 (0.81) | 0.8 (0.92) | 2.1 (0.73) | 5.3 (0.41) | -0.3 (0.97) | -0.1 (0.99) |
| Location: PF vs ST* 28/12 | -2.1 (0.75) | 1.1 (0.89) | -3.9 (0.56) | -6.2 (0.37) | -5.2 (0.52) | 1.1 (0.88) |
| Gastric tube* (33/7) | 25.5 (<0.001) | 31.6 (<0.001) | 22.2 (0.003) | 5.7 (0.49) | 35.0 (<0.001) | 25.9 (0.002) |
| EVD/shunt* 27/13 | 17.1 (0.007) | 20.2 (0.008) | 15.6 (0.012) | 7.6 (0.25) | 24.3 (0.001) | 13.0 (0.06) |
| Chemotherapy* 16/24 | 2.6 (0.68) | 1.1 (0.88) | 3.4 (0.58) | 1.5 (0.82) | 7.2 (0.35) | 0.1 (0.99) |
| IT/High dose* chemotherapy 30/10 | 1.7 (0.81) | 0.3 (0.97) | 2.8 (0.69) | 4.2 (0.56) | -2.7 (0.76) | 3.6 (0.64) |
| Involved field vs CSI* 5/35) | -4.3 (0.65) | -4.5 (0.69) | -4.0 (0.66) | -5.3 (0.58) | -9.3 (0.40) | 1.2 (0.90) |
| PRT dose** | 0.198 (0.22) | 0.203 (0.21) | 0.176 (0.28) | 0.279(0.08) | 0.073 (0.66) | 0.149 (0.36) |
Relationship assessed using the paired T-test for categorical variables*, and Pearson correlation coefficient for continuous variables**. Statistical significance measures are highlighted in bold.
Abbreviations: F, female; M, male; PF, Posterior Fossa, ST, Supratentorial, EVD, extraventricular drain; IT, intrathecal; CSI, craniospinal irradiation; PRT, proton therapy